- Home
- OM vs BLRX Comparison
OM vs BLRX Comparison
Compare OM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- BLRX
- Stock Information
- Founded
- OM 2003
- BLRX 2003
- Country
- OM United States
- BLRX Israel
- Employees
- OM N/A
- BLRX N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- BLRX Health Care
- Exchange
- OM Nasdaq
- BLRX Nasdaq
- Market Cap
- OM 31.8M
- BLRX 36.0M
- IPO Year
- OM 2020
- BLRX 2011
- Fundamental
- Price
- OM $0.76
- BLRX $0.32
- Analyst Decision
- OM Buy
- BLRX Strong Buy
- Analyst Count
- OM 4
- BLRX 2
- Target Price
- OM $4.38
- BLRX $11.50
- AVG Volume (30 Days)
- OM 991.6K
- BLRX 880.1K
- Earning Date
- OM 11-06-2024
- BLRX 11-25-2024
- Dividend Yield
- OM N/A
- BLRX N/A
- EPS Growth
- OM N/A
- BLRX N/A
- EPS
- OM N/A
- BLRX N/A
- Revenue
- OM $114,729,000.00
- BLRX $17,048,000.00
- Revenue This Year
- OM N/A
- BLRX N/A
- Revenue Next Year
- OM $11.81
- BLRX N/A
- P/E Ratio
- OM N/A
- BLRX N/A
- Revenue Growth
- OM N/A
- BLRX N/A
- 52 Week Low
- OM $0.44
- BLRX $0.32
- 52 Week High
- OM $6.37
- BLRX $1.89
- Technical
- Relative Strength Index (RSI)
- OM 54.84
- BLRX 34.04
- Support Level
- OM $0.67
- BLRX $0.44
- Resistance Level
- OM $0.79
- BLRX $0.56
- Average True Range (ATR)
- OM 0.10
- BLRX 0.04
- MACD
- OM 0.00
- BLRX 0.00
- Stochastic Oscillator
- OM 46.56
- BLRX 1.46
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.